CurrentUnitedHealthcarePolicy CS007.W

Bariatric Surgery Coverage Criteria

UnitedHealthcare medical policy CS007.W defines medical necessity criteria, covered and not-covered bariatric surgical procedures, indications for adults and adolescents, revisional and two-stage procedures, documentation requirements, and applicable procedure codes. This part (1 of 7) contains coverage rationale, definitions, descriptions of procedures, and clinical evidence summaries and lists applicable CPT/other codes referenced for billing guidance.

Policy Summary

PayerUnitedHealthcare

PolicyBariatric Surgery Coverage Criteria

Policy CodePolicy CS007.W

Change TypeRevised / Clarified (code and application updates)

Effective DateApr 1, 2025

Next Review Date

Key ActionDocument detailed weight history, dietary and physical activity patterns, and psychosocial-behavioral evaluation by a qualified behavioral health professional; these are required to meet medical necessity.

SourceLink

POLICY UPDATE CHANGES

04/01/2025 Updated Medical Records Documentation Used for Reviews reference link and added CPT code 43999 to Applicable Codes; updated Description of Services, Clinical Evidence, and References; archived previous policy version CS007.V.

06/01/2025 Application update: policy does not apply to Idaho and Kansas; refer to state-specific versions.

07/01/2025 Template Update removed content/language pertaining to the state of Mississippi.

04/01/2026 Template Update removed content/language pertaining to the state of Louisiana and updated related policy links.

4Procedures listed as proven/medically necessary

10+Procedure codes listed

many

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Procedures listed as unproven/not medically necessary

6.3%Revision/conversion rate example

31%Early explant rate (DJBL cohort)

Coverage Summary

Overview: This policy (CS007.W) defines coverage criteria for metabolic and bariatric surgery and related device-based/endoscopic weight-loss therapies, including adult and adolescent clinical thresholds, procedure definitions, and documentation requirements. Effective Date: April 1, 2025.

Scope and covered populations: The policy applies to adults (age ≥ 18) and adolescents (age 12–17) and specifies BMI-based indications (e.g., Adults: BMI ≥ 40 kg/m2 or BMI 35.0–39.9 kg/m2 with qualifying comorbidity; adolescent criteria mirror pediatric society guidance and require multidisciplinary center evaluation).

High-level stance: Coverage stance is mixed — several standard bariatric surgical procedures (e.g., RYGB, sleeve gastrectomy, LAGB, BPD/DS) are described as proven and medically necessary when criteria are met, while many device-based and endoscopic interventions (e.g., certain balloons, DJBL/EndoBarrier, GES, VBLOC, TPS, aspiration therapy, BAE, LGCP, OAGB/MGB, SADI-S in some contexts) are characterized as having insufficient or mixed evidence and considered unproven/not medically necessary for routine treatment of obesity.

Applicability notes and exclusions: The policy does not apply to certain state-specific versions; specifically, Idaho and Kansas are excluded and should be referred to state-specific policies. Per revisions, references/language pertaining to Louisiana and Mississippi were removed in 2026 and 2025 template updates, respectively.

Quick thresholds & facts

Adult BMI (Class III)≥ 40 kg/m2 (≥ 37.5 kg/m2 in individuals of Asian descent)

Adult BMI (Class II) with comorbidity35.0–39.9 kg/m2 (32.5–37.4 kg/m2 in individuals of Asian descent) + ≥1 qualifying comorbidity

Adolescent age threshold> 12 years (adolescents 12–17 evaluated per pediatric criteria)

IGB maximum duration6 months (maximum implant duration)

Planned two-stage - initial BMIInitial BMI ≥ 50 kg/m2 prior to first stage

Planned two-stage - intervalSecond stage occurs within 2 years following the primary bariatric surgery

% Reoperation (ASMBS review)6.3% of bariatric operations underwent reoperation

Procedures listed as proven/medically necessary (count)4 procedures listed as proven/medically necessary

Procedures listed as unprovenMany procedures described as unproven or not medically necessary (e.g., IGB, BAE, GES, LGCP, OAGB, SADS, aspiration, ESG, VBLOC, GI liners)

Adults (age ≥ 18) — Medical-Necessity Criteria

Covered when ALL of the following are met:

ALL of the following

BMI criteria
- BMI ≥ 40 kg/m2 (or BMI ≥ 37.5 kg/m2 in individuals of Asian descent)≥ 40 kg/m2 / ≥ 37.5 kg/m2 (Asian)
- BMI 35.0–39.9 kg/m2 (or BMI 32.5–37.4 kg/m2 in individuals of Asian descent) with one or more qualifying obesity-related comorbidities35.0–39.9 kg/m2 / 32.5–37.4 kg/m2 (Asian)
Qualifying comorbidities (one or more)

Adolescents (age 12–17) — Medical-Necessity Criteria

Adolescents (age 12–17) - Medical Necessity for Bariatric Surgery

Bariatric surgery is proven and medically necessary for adolescents when ALL of the following criteria are met:

ALL of the following

One of the following obesity severity criteria
- Class III obesity (BMI ≥ 40 kg/m2 or ≥140% of 95th percentile for age/sex, whichever is lower)Age 12–17 applicable
  AAP/ASMBS pediatric classifications; Tanner stage referenced in society guidance
- Class II obesity plus comorbidity: Class II obesity (BMI 35–39.9 kg/m2 or ≥120% of 95th percentile for age/sex) in the presence of one or more qualifying comorbidities
  Comorbidities include T2D, poorly controlled HTN, hyperlipidemia, OSA (AHI ≥30), NAFLD, idiopathic intracranial hypertension; see definitions for OSA thresholds

Planned Two-Stage Procedure — Medical Necessity

Planned Two-Stage Procedure - Medical Necessity

A planned two-stage procedure is proven and medically necessary when ALL of the following are met:

ALL of the following

Initial BMI ≥ 50 kg/m2 prior to first stage bariatric procedure≥ 50 kg/m2
Second stage timing: Second stage occurs within 2 years following the primary bariatric surgery procedureWithin 2 years
Compliance: Individual has been compliant with nutrition and exercise
Documentation of compliance recommended

Revisional Bariatric Surgery — Medical Necessity

Revisional Bariatric Surgery - Medical Necessity

Revisional surgery using covered procedures is proven and medically necessary when due to a technical failure or major complication from the initial procedure (examples listed); additional specific criteria apply for certain indications:

ANY of the following

Technical failures/major complications: Technical failures or major complications from the initial procedure (examples) — documentation required
Examples include bowel perforation (including adjustable gastric band erosion); adjustable gastric band migration/slippage that cannot be corrected with manipulation or adjustment (records must demonstrate that manipulation or adjustment was attempted); leak; obstruction (confirmed by imaging); staple-line failure; mechanical adjustable gastric band failure
Uncontrollable reflux related to sleeve gastrectomy
- Maximum nonpharmacological management failure: Maximum nonpharmacological medical management failure (e.g., positional, dietary modification, and behavioral changes)

Unproven / Not Medically Necessary Procedures

Society Recommendations and Guideline Guidance

Society recommendations for metabolic/bariatric surgery candidacy (adult)

Recommendations from major societies regarding adult metabolic/bariatric surgery candidacy and BMI thresholds (including ancestry adjustments):

ANY of the following

Recommend MBS (Class III): BMI ≥ 40 kg/m2 (Class III obesity) — recommended regardless of glycemic control or regimen complexity≥ 40 kg/m2
ADA/Joint statements/IFSO/ASMBS guidance
Recommend MBS with comorbidity (Class II): BMI 35.0–39.9 kg/m2 (Class II obesity) with inadequately controlled hyperglycemia or significant comorbidity despite lifestyle and optimal medical therapy — recommend MBS35.0–39.9 kg/m2
Society guidance

Procedures, Devices and Device-Specific Guidance

Intragastric balloon (IGB) recommendations (AGA / ASMBS / ASGE)

Guidance on intragastric balloon (IGB) use and recommended adjunctive measures (AGA / ASMBS / ASGE):

ALL of the following

Candidate selection and adjunctive lifestyle therapy: IGB therapy suggested for individuals with obesity who failed conventional weight-loss strategies and should be used with moderate- to high-intensity lifestyle modification interventions to maintain and augment weight loss
AGA conditional/moderate certainty; ASMBS notes device is temporary adjunct
PPI prophylaxis: Recommend prophylaxis with proton pump inhibitors during IGB therapy
AGA strong recommendation
Antiemetic strategies:

Clinical Evidence Summary

High-level evidence synthesis: The evidence base for conventional bariatric operations includes randomized trials, systematic reviews/meta-analyses, and large long-term cohort series. RCTs and meta-analyses (e.g., Cochrane 2014, Alghamdi 2022, Salminen/SLEEVEPASS) show bariatric surgery yields greater weight loss and comorbidity improvement than non-surgical care, with moderate-quality evidence overall; comparative RCTs generally find RYGB and sleeve gastrectomy (LSG/SG) produce similar weight-loss and metabolic effects in many settings, though RYGB may be superior for GERD and some cardiometabolic endpoints.

Long-term cohort outcomes and examples: Large observational and long-term series report sustained substantial weight loss for several procedures (examples from long-term analyses: RYGB ~~56.7% EWL at ≥10 years; BPD/DS ~~74.1% EWL; selected SG reports ~~57% EWL in long-term cohorts), while procedure-specific long-term issues include weight recidivism and need for revisional surgery (e.g., LAGB high removal/conversion rates, SG revision rates and GERD/Barrett’s in long-term follow-up).

Endoscopic and device evidence limitations: For many device/endoscopic therapies and newer surgical variants (e.g., DJBL, ESG, TPS, GES, vBloc, OAGB/MGB, SADI-S), evidence is often limited by small sample sizes, short follow-up, high risk of bias, and heterogeneous outcomes; randomized data are scarce or short-term for many technologies and safety signals (e.g., hepatic abscess with DJBL, early removals and gastrointestinal AEs with IGBs) and weight regain after device removal are recurrent limitations.

Comparative and revisional findings: Systematic reviews of revisional procedures show revisional RYGB, OAGB, SADI-S, and DS can produce meaningful further weight loss and metabolic benefit after failure of restrictive procedures, but heterogeneity, bias, and higher operative risks limit confidence; network/meta-analytic data suggest BPD/DS and some malabsorptive procedures achieve greater %EWL but with higher nutritional deficiency risk.

Pediatric/adolescent evidence: Moderate-sized observational cohorts and registries (e.g., Teen-LABS, MBSAQIP adolescent data, Alqahtani) show durable weight loss and comorbidity improvement in adolescents following RYGB and LSG with low short-term complication rates, but long-term randomized comparative data remain limited and nutritional/bone-health monitoring is emphasized.

Definitions

Term	Definition
MBSAQIP
Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program: a national accreditation standard for bariatric surgical centers established by the American College of Surgeons and ASMBS to ensure resources, personnel, and outcome reporting to a central database.

Coding — Applicable and Referenced Codes

Referenced / Applicable CPT and other procedure codes (informational list)mixed

0813T	Esophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon.
43290	Esophagogastroduodenoscopy, flexible, transoral; with deployment of intragastric bariatric balloon.
43291	Esophagogastroduodenoscopy, flexible, transoral; with removal of intragastric bariatric balloon(s).
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less).
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43659	Unlisted laparoscopy procedure, stomach.
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (e.g., gastric band and subcutaneous port components).
43771	Laparoscopy, surgical, gastric restrictive procedure; revision of adjustable gastric restrictive device component only.

1–10 of 30

1/3

Added/Referenced CPT codesCPT

43999

Unlisted procedure, stomach — Added to Applicable Codes per 04/01/2025 revision

Provider Actions and Requirements

Documentation Required

Multidisciplinary center evaluation (adolescents)

Adolescents (age 12-17) must receive an evaluation at, or in consultation with, a Multidisciplinary center focused on the surgical treatment of severe childhood obesity. Centers may be MBSAQIP-accredited adolescent/metabolic and bariatric programs or demonstrate equivalent programmatic components (bariatric surgeon, obesity medicine specialist, registered dietitian, behavioral health specialist, specialized nursing, exercise specialist and appropriate support services). Document consultation or evaluation in the medical record.

Documentation Required

Records for adjustable gastric band slippage

When adjustable gastric band slippage or migration is suspected, include complete records demonstrating attempts at nonoperative correction (manipulation/adjustment) and the clinical rationale for removal or revisional surgery. Operative notes, imaging, endoscopy reports, and records of band adjustments must be provided.

Include manipulation/adjustment attempt documentation
Provide imaging or endoscopy confirming slippage/migration
Operative note if removal or revision performed

Perioperative and Preoperative Guidance

Perioperative and preoperative guidance (ASMBS / AACE / Others)

Perioperative and preoperative guidance from ASMBS, AACE and others:

ALL of the following

Comprehensive preoperative evaluation including an obesity-focused history, physical exam, pertinent laboratory and diagnostic testing, detailed weight history, and documentation of prior weight-loss attempts
AACE/ASMBS recommend detailed documentation
Psychosocial assessment: Preoperative psychosocial assessment by specialized behavioral health clinicians; establish pre- and postoperative behavioral health connections and long-term follow-up
ASMBS recommends behavioral health involvement
No mandated preoperative weight loss: ASMBS position: no evidence supports mandated preoperative weight loss; evaluate patients on BMI and comorbid conditions rather than requiring mandatory preoperative weight loss

Revision History

04/01/2025revised

Updated Medical Records Documentation Used for Reviews reference link and added CPT code 43999 to Applicable Codes; updated Description of Services, Clinical Evidence, and References; archived previous policy version CS007.V; CPT 43999 added

06/01/2025clarified

Application update: policy does not apply to Idaho and Kansas; refer to state-specific versions

07/01/2025revised

Policy Summary

PayerUnitedHealthcare

PolicyBariatric Surgery Coverage Criteria

Policy CodePolicy CS007.W

Change TypeRevised / Clarified (code and application updates)

Effective DateApr 1, 2025

Next Review Date

SourceLink

On This Page

Insulin resistance or Type 2 diabetes

Cardiovascular disease (e.g., history of stroke and/or myocardial infarction, poorly controlled hypertension despite pharmacotherapy, coronary artery disease, hyperlipidemia)

History of cardiomyopathy

Obstructive sleep apnea (OSA) confirmed on polysomnography with an AHI or RDI ≥ 30

Evidence of nonalcoholic fatty liver disease (NAFLD)

Idiopathic intracranial hypertension (pseudotumor cerebri)

Preoperative evaluation requirements

Standard preoperative evaluation
- Completion of a preoperative evaluation that includes a detailed weight history and assessment of dietary and physical activity patterns
- Psychosocial-behavioral evaluation by a behavioral health professional recognized to screen for risk factors or potential postoperative challenges
Participation in a multidisciplinary surgical preparatory regimen

ALL of the following

Revisional bariatric surgery — indications
- Technical failure or major complication from the initial procedure (examples include bowel perforation, adjustable gastric band erosion, staple-line failure, leak, obstruction confirmed by imaging, mechanical adjustable gastric band failure)
- Adjustable gastric band migration (slippage) that cannot be corrected with manipulation or adjustment (documentation must demonstrate attempt at manipulation/adjustment)
- - Maximum nonpharmacological management has failed (e.g., positional, dietary modification, behavioral changes)
  - Maximum pharmacological management has failed (e.g., at least one month of double-dose PPI, H2 blocker, and/or sucralfate)
  - Severe esophagitis (Grade C or D) confirmed by endoscopy despite maximum medical management
Removal of adjustable gastric band and all related components which does not result in a revisional surgery is proven and medically necessary.

Procedures considered unproven/not medically necessary

Duodenal-jejunal bypass sleeve (DJBL / EndoBarrier) — evidence summary: available randomized and nonrandomized studies show short-term weight loss and glycemic improvements, but evidence is limited by small sample sizes, device-related adverse events (including hepatic abscess), high rates of device explantation, and insufficient long-term safety and durability data. Therefore DJBL/EndoBarrier and other gastrointestinal liners are considered unproven and not medically necessary for treating obesity due to insufficient evidence of long-term efficacy and safety.
Other interventions with insufficient evidence include bariatric artery embolization, gastric electrical stimulation with implantable gastric stimulator, intragastric balloons, laparoscopic greater curvature plication, mini-gastric bypass/one-anastomosis gastric bypass, single-anastomosis duodenal switch (SIPS), stomach aspiration therapy, transoral endoscopic surgery (including TransPyloric Shuttle®, endoscopic sleeve gastroplasty), vagus nerve blocking (VBLOC®), and other gastrointestinal liners.

Multidisciplinary center evaluation: Evaluation at, or consultation with, a Multidisciplinary center focused on surgical treatment of severe childhood obesity (may include MBSAQIP-accredited adolescent centers or centers demonstrating similar programmatic components)

Age and Tanner stage notes: society guidance requires Tanner stage 4–5 and near-final adult height in some society statements; AAP recommends >12 years; include as note/threshold for pediatric readiness

Medical necessity at second stage: Individual meets medical necessity criteria listed for bariatric surgery at time of second stage procedure

Must meet same medical necessity criteria as for primary procedure

Maximum pharmacological management failure: Maximum pharmacological medical management failure (e.g., at least one month of double dose PPI, H2 blocker, and/or sucralfate)At least one month

Severe esophagitis confirmed: Severe esophagitis (Los Angeles grade C or D) confirmed by endoscopy despite maximum medical managementLA grade C or D

Endoscopy documentation required

Band removal: Removal of adjustable gastric band and all related components which does not result in revisional surgery is proven and medically necessary

Documentation of band components removal recommended

Consider MBS (lower BMI): BMI 30–34.9 kg/m2 with type 2 diabetes or metabolic disease and inadequate glycemic control despite optimal therapy — consider/option for MBS30.0–34.9 kg/m2

Selected society statements; evidence variable

Adjust BMI thresholds by ancestry: For Asian populations, reduce BMI thresholds by ~2.5 kg/m2 (e.g., BMI ≥ 37.5 -> ≥35; or Class II thresholds reduced by ~2.5 kg/m2)Reduce BMI thresholds by ~2.5 kg/m2 for Asian ancestry

ADA/IFSO/NICE note ancestry-specific adjustments

Pediatric/adolescent MBS candidacy (AAP / ASMBS / Endocrine Society)

Society criteria and recommendations for pediatric/adolescent MBS candidacy, exclusions, and evaluation requirements:

ANY of the following

AAP recommendations: AAP: Age > 12 years and criteria for Class II or Class III obesity (Class II: BMI ≥ 35 or 120% of 95th percentile with clinically significant disease; Class III: BMI ≥ 40 or 140% of 95th percentile)Age > 12 years; BMI percentiles/absolute BMI per AAP
Refer to AAP 2023 guideline
Endocrine Society suggested conditions: Endocrine Society: patient at Tanner stage 4 or 5 with final/near-final adult height; BMI >40 or BMI >35 with significant/extreme comorbidities (T2DM, moderate-extreme OSA, pseudotumor cerebri, debilitating orthopedic problems, NASH with advanced fibrosis); failure of formal lifestyle modification; psychological evaluation confirming family stability and ability to adhere; access to experienced pediatric bariatric center with long-term follow-up capabilityTanner stage 4–5 and near-final height where required by Endocrine Society
Endocrine Society exclusions apply (see next node)
Endocrine Society absolute exclusions: Do not perform MBS in preadolescent children, pregnant or breastfeeding adolescents, patients planning pregnancy within 2 years, or those with unresolved substance abuse, eating disorder, or untreated psychiatric disorder
Endocrine Society exclusions

Suggest perioperative antiemetic strategies and scheduled antiemetics for approximately 2 weeks post-placement

~2 weeks for scheduled antiemetics

AGA conditional recommendation

Implant duration: IGB implant maximum duration — temporary tool; FDA/ASMBS: maximum 6 monthsMaximum 6 months

Orbera FDA indication; ASMBS emphasizes timely removal

Monitoring and supplementation: Suggest daily multivitamin supplementation (1–2 adult doses) after IGB placement; suggest individualized post-removal weight-loss/maintenance interventions; suggest against routine perioperative lab screening for nutritional deficiencies (conditional)

Monitoring and follow-up essential; discuss risks including early removal and device intolerance

Device- and endoscopic-therapy summary: Some endoscopic and device therapies have regulatory approvals and randomized-trial evidence for short-term efficacy but important device-specific safety signals and durability limitations. The Orbera intragastric balloon (IGB) is FDA-approved (Orbera indicated for adults BMI ≥ 30 and ≤ 40; maximum placement 6 months) and meets ASGE PIVI thresholds in pooled analyses (%EWL at 12 months ~25.44%, pooled %TWL ~13% at 6 months), but long-term maintenance of weight loss is uncertain and AEs / early removals are common; societies recommend concomitant lifestyle programs and PPI prophylaxis during IGB therapy.

TransPyloric Shuttle (TPS) and other transoral endoscopic devices: The TPS received FDA PMA (April 18, 2019) for adults with BMI 35.0–40.0 or 30.0–34.9 with comorbidity; evidence includes small RCTs and case series demonstrating short-term weight loss but requiring independent confirmation and longer follow-up — overall evidence is inconclusive and safety/ durability data are limited.

Gastrointestinal liners / DJBL (EndoBarrier): DJBL studies show superior short-term weight and cardiometabolic effects in some trials/cohorts but have significant safety concerns (including hepatic abscess, GI hemorrhage, device obstruction) and high early explant rates (e.g., cohort with 31% early explant and AE ~17%); NICE and other guidance restrict use to research settings.

Gastric electrical stimulation (GES), vagus nerve blocking (vBloc), and other implantable neurostimulation: Trials show modest weight-loss signals and some metabolic effects (e.g., Exilis/CLGES and ReCharge/vBloc), but mixed efficacy on prespecified endpoints and limited durability; implant-site pain, heartburn/dyspepsia, lead/system complications and device replacements are reported, and further robust RCTs with longer follow-up are recommended.

Aspiration therapy and bariatric artery embolization (BAE): Aspiration therapy (AspireAssist) has randomized and extension data demonstrating clinically meaningful TBWL maintained up to several years in selected cohorts (pooled SAE ~4.1%); BAE RCTs show modest short-term TBWL (example: 7.4 kg vs 3.0 kg at 6 months) but require larger trials to define durability and safety.

Transoral and endoscopic suturing (ESG/OverStitch): ESG produces clinically significant but generally lower weight loss than LSG in RCTs/observational comparisons (short-to-mid term), with SAE rates reported in the low single digits (~2%); longer-term comparative data are limited.

Regulatory and society-position context: Several devices have specific FDA clearances (e.g., Orbera, TPS) or IDE/CE history (DJBL) and societies (ASGE, ASMBS, AGA, NICE) provide conservative recommendations — endorsing use as adjuncts or within research frameworks where evidence/safety concerns persist. Overall, device choice requires informed consent about device-specific risks (spontaneous deflation, bowel obstruction, hepatic abscess, implant-site pain, lead failure) and planning for follow-up and adjunctive lifestyle/pharmacologic therapies.

Limitations and guidance summary: Key limitations across the evidence are short follow-up in many RCTs, heterogeneity in outcome measures (%EWL, %TWL, %EBMIL), bias in observational studies, and variable reporting of adverse events. Clinical guidelines and technology reviews call for longer-term RCTs and careful multidisciplinary patient selection, noting that durability, comparative effectiveness, and long-term safety differ by procedure.

Selected quantitative evidence metrics

Orbera (12‑month pooled %EWL)25.44% (95% CI 21.45 to 29.41%)

DJBL cohort mean weight loss12.8 ± 8.0 kg (11.9 ± 6.9% TBWL) in cohort with intended 12‑month implant

OAGB revisional %EWL (selected)50.8% at 6 mo; 65.2% at 1 yr; 68.5% at 24 mo; 71.6% at 5 yr (systematic review of revisional OAGB)

Long-term %EWL (RYGB, BPD/DS, SG)RYGB ~56.7% at ≥10 yr; BPD/DS ~74.1% at ≥10 yr; SG ~57.0% (O'Brien et al. 2019)

SADI-S EWL rangeEWL up to 70.9%–88.7% at 6 years (IFSO evidence summary)

Billing Rule

Coding clarification for sleeve gastrectomy

Clarify coding for sleeve gastrectomy and related procedures to ensure correct billing and benefit determination. Document the specific procedure performed (e.g., vertical sleeve gastrectomy, conversion/revisional sleeve) and use the appropriate CPT/ICD-10 codes on claims and in the medical record.

Document exact operative name and approach (laparoscopic vs open)
Include conversion/revisional status when applicable
Ensure CPT/ICD-10 codes on claim match operative report

Prior Authorization

Use of certain procedures only in research or special arrangements

Some bariatric procedures and devices are considered investigational or only available through research or special contractual arrangements. Prior authorization and evidence review may be required; do not assume coverage. Confirm coverage via prior authorization when considering procedures listed as unproven.

Examples include: intragastric balloon, endoscopic sleeve gastroplasty, gastric electrical stimulation, mini-gastric/one-anastomosis bypass, gastrointestinal liners, vagus nerve blocking
Verify if a research protocol or special agreement is needed before scheduling

Note

Evidence limitations require careful patient selection and counseling

Evidence limitations exist for several emerging bariatric interventions. Careful patient selection, informed consent about uncertain benefits/risks, and consideration of established alternatives are required when contemplating these procedures.

Discuss limited long-term outcomes and potential need for future revision
Document patient understanding and rationale for selecting an investigational approach

Documentation Required

Comprehensive preoperative evaluation and documentation

Preoperative evaluation must be comprehensive and documented: detailed weight history, dietary and activity patterns, medical comorbidities, prior weight-loss attempts, and laboratory/imaging assessments. Documentation should support meeting medical necessity criteria.

Detailed weight history and prior interventions
Dietary and physical activity assessment
Relevant labs and imaging (as clinically indicated)

Documentation Required

Psychosocial evaluation and follow-up plan

Psychosocial and behavioral evaluation is required preoperatively by a qualified behavioral health professional. A follow-up plan for postoperative behavioral support and monitoring should be documented, including plans for substance use screening and management of mental health risks.

Preoperative behavioral health screening and risk identification
Documented follow-up plan for postoperative psychosocial support
Assess for eating disorders, substance use, and adherence risks

Documentation Required

Informed consent and counseling for device risks

When devices (e.g., adjustable gastric band) are used, obtain informed consent that specifically addresses device risks, potential complications (erosion, slippage, migration), need for future interventions, and device removal implications. Document that risks were discussed and that the member/caregiver understood alternatives.

Document device-specific risks and possible need for removal or revision
Include discussion of alternative treatments and long-term implications

Documentation Required

Multidisciplinary evaluation and long-term follow-up

Multidisciplinary evaluation and long-term follow-up must be documented. The plan should include medical, nutritional, behavioral, and surgical follow-up components and specify which team members will provide ongoing care and monitoring of outcomes and complications.

Specify multidisciplinary team members and roles
Document planned follow-up intervals and monitoring strategy

Documentation Required

Preoperative psychological evaluation

Preoperative psychological evaluation by a behavioral health professional is required to identify factors that may affect postoperative outcomes and to document readiness for surgery.

Assessment of mental health, coping, support systems, and adherence potential
Documentation of clearance or documented plan to address concerns

Note

Check federal/state/contractual requirements

Confirm and document federal, state, and contract-specific coverage requirements before performing bariatric procedures. Benefit determination may vary by state and contract; medical record documentation alone does not guarantee coverage.

Check member's plan, state-specific policy exceptions, and contractual provisions
Obtain prior authorization when indicated by contract or procedure type

Note

Evidence-based consideration for procedures

When considering procedures with limited evidence, evaluate current literature and registry data and document evidence-based rationale for patient selection. Prefer procedures with proven efficacy and safety for standard coverage.

Document literature support or lack thereof for selected procedure
Consider enrollment in registries or clinical trials when appropriate

Documentation Required

Pediatric/adolescent surgery outcomes and monitoring

Monitor pediatric/adolescent surgical outcomes and include these data in the member record when available. Documentation should reflect growth/weight trajectories, nutritional status, complications, and psychosocial outcomes to support ongoing care and potential coverage decisions.

Track BMI percentiles, growth parameters, and nutrition labs
Record postoperative complications and behavioral outcomes

Preoperative weight loss may be considered to reduce liver volume when clinically relevant but not mandated

Nutritional screening and monitoring: Nutritional screening preoperatively and plan for postoperative nutritional monitoring and supplementation; optimize micronutrient status pre- and post-op

ASMBS integrated health nutritional guidelines recommend screening and follow-up

Documentation Required

Nutritional screening and monitoring

Nutritional screening should include assessment for micronutrient deficiencies preoperatively and documentation of a plan for postoperative monitoring and supplementation. For intragastric balloon therapy, document recommendation for daily multivitamin supplementation and a plan to monitor and manage deficiencies over time.

Document baseline micronutrient lab results (e.g., vitamin D, iron, B12, folate, albumin)
Specify supplementation plan (e.g., daily multivitamin for IGB)
Provide schedule for postoperative nutritional monitoring and responsible clinician

Template Update removed content/language pertaining to the state of Mississippi

04/01/2026revisedLatest

Template Update removed content/language pertaining to the state of Louisiana and updated related policy links